iwNHL 2023 Session II: The evolving treatment landscape in mantle cell lymphoma
Nov 3, 2023
auto_awesome
In this podcast, experts Stephen Ansell and Marek Trněný discuss the evolving treatment landscape in mantle cell lymphoma. They explore the impact of stem cell transplants, the emergence of novel therapies, and the importance of maintenance therapy. Different treatment approaches, including CAR T cell therapy, are also discussed along with the potential for cure and long-term survival rates.
The incorporation of BTK inhibitors, like Ibrutinib, in frontline treatment for mantle cell lymphoma has shown impressive results in both transplant-eligible and transplant-ineligible populations.
The addition of a BTK inhibitor to maintenance therapy, such as Retuximab, in mantle cell lymphoma has shown benefit in both induction and maintenance settings, although optimal timing and combination are still being evaluated.
Deep dives
The Future of Autologous Stem Cell Transplant
The podcast discusses the evolving treatment landscape in mantle cell lymphoma. One of the main topics covered is the future of autologous stem cell transplant. The experts highlight the impact of novel therapies, such as BTK inhibitors, in changing the standard of care for mantle cell lymphoma. They discuss the incorporation of BTK inhibitors, like Ibrutinib, in frontline treatment and its impressive results in both transplant-eligible and transplant-ineligible populations.
Role of Maintenance Therapy
The podcast explores the importance of maintenance therapy in mantle cell lymphoma. Retuximab maintenance has been a standard treatment, but the experts discuss the potential benefit of adding a BTK inhibitor to the maintenance regimen. They highlight that the data from studies like the triangle trial show the benefit of BTK inhibitors in both induction and maintenance settings. However, the optimal timing and combination of these treatments are still being evaluated.
Cellular Therapies and the Changing Landscape
The podcast touches upon the emergence of cellular therapies in treating mantle cell lymphoma. The experts discuss the use of CAR T-cell products, such as brexucabtagene autoleucel (Brexcell), in relapsed or refractory settings, specifically after BTK inhibitor failure. They also mention ongoing studies exploring the use of CAR T-cell therapy in the front-line setting for high-risk patients. Additionally, the podcast highlights promising data on a bispecific antibody called golfitamab, which may have potential for frontline use as well. The experts express optimism about the curative potential of these novel therapies, particularly for low and some intermediate-risk patients.
The 20th International Workshop on Non-Hodgkin Lymphoma (iwNHL 2023) took place in Miami, FL, and brought together leading experts as they discussed the latest clinical updates in the field. In this podcast series, you will hear the latest advances in the treatment and management of lymphoma and gain an insight into the sessions that took place at this year’s meeting.
In this podcast, Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MN, Marek Trněný, MD, PhD, Charles University, Prague, Czech Republic, John Kuruvilla, MD, Princess Margaret Cancer Centre, Toronto, Canada, and Yucai Wang, MD, PhD, Mayo Clinic, Rochester, MN, share some insights into the evolving treatment landscape in mantle cell lymphoma (MCL), commenting on the changing role of transplantation and the impact of novel agents.